BASF subsidiary Metanomics Health launches MetaMap®Tox
Published: Monday, August 13, 2012 Last Updated: Monday, August 13, 2012
MetaMap®Tox is a service evaluating specific metabolomic patterns in vivo, enabling customers to better and faster identify potential safety risks of test compounds in in vivo studies of rats.
Developed in-house by BASF’s Experimental Toxicology and Ecology unit and marketed through Metanomics Health, MetaMap®Tox addresses key unmet needs for in vivo toxicology testing: predictability, understanding of a toxicology mechanism and the ability for translation to clinical use.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.